Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety profile of new anticancer drugs.
Mansi L, Thiery-Vuillemin A, Nguyen T, Bazan F, Calcagno F, Rocquain J, Demarchi M, Villanueva C, Maurina T, Pivot X. Mansi L, et al. Among authors: calcagno f. Expert Opin Drug Saf. 2010 Mar;9(2):301-17. doi: 10.1517/14740330903530663. Expert Opin Drug Saf. 2010. PMID: 20175699 Review.
First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case report.
Meynard G, Mansi L, Lebahar P, Villanueva C, Klajer E, Calcagno F, Vivalta A, Chaix M, Collonge-Rame MA, Populaire C, Algros MP, Colpart P, Neidich J, Pivot X, Curtit E. Meynard G, et al. Among authors: calcagno f. Oncol Rep. 2017 Mar;37(3):1573-1578. doi: 10.3892/or.2017.5422. Epub 2017 Feb 3. Oncol Rep. 2017. PMID: 28184945
Metronomic cyclophosphamide induces regulatory T cells depletion and PSA-specific T cells reactivation in patients with biochemical recurrent prostate cancer.
Laheurte C, Thiery-Vuillemin A, Calcagno F, Legros A, Simonin H, Boullerot L, Jacquin M, Nguyen T, Mouillet G, Borg C, Adotévi O. Laheurte C, et al. Among authors: calcagno f. Int J Cancer. 2020 Aug 15;147(4):1199-1205. doi: 10.1002/ijc.32803. Epub 2019 Dec 11. Int J Cancer. 2020. PMID: 31749145 Free article.
Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practice.
Mouillet G, Falcoz A, Fritzsch J, Almotlak H, Jacoulet P, Pivot X, Villanueva C, Mansi L, Kim S, Curtit E, Meneveau N, Adotevi O, Jary M, Eberst G, Vienot A, Calcagno F, Pozet A, Djoumakh O, Borg C, Westeel V, Anota A, Paget-Bailly S. Mouillet G, et al. Among authors: calcagno f. Qual Life Res. 2021 Nov;30(11):3255-3266. doi: 10.1007/s11136-020-02721-0. Epub 2021 Jan 2. Qual Life Res. 2021. PMID: 33387291
Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial.
Mouillet G, Paillard MJ, Maurina T, Vernerey D, Nguyen Tan Hon T, Almotlak H, Stein U, Calcagno F, Berthod D, Robert E, Meurisse A, Thiery-Vuillemin A. Mouillet G, et al. Among authors: calcagno f. Trials. 2018 Apr 12;19(1):221. doi: 10.1186/s13063-018-2613-8. Trials. 2018. PMID: 29650037 Free PMC article.
FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study.
Vienot A, Chevalier H, Bolognini C, Gherga E, Klajer E, Meurisse A, Jary M, Kim S, d'Engremont C, Nguyen T, Calcagno F, Almotlak H, Fein F, Nasri M, Abdeljaoued S, Turpin A, Borg C, Vernerey D. Vienot A, et al. Among authors: calcagno f. World J Gastrointest Oncol. 2020 Mar 15;12(3):332-346. doi: 10.4251/wjgo.v12.i3.332. World J Gastrointest Oncol. 2020. PMID: 32206183 Free PMC article.
36 results